申请人:Youngs Wiley
公开号:US09278951B2
公开(公告)日:2016-03-08
Singly and multiply charged imidazolium cations (ICs) have been identified as a class of chemical compositions that possess potent antineoplastic, antibacterial and antimicrobial properties. The imidazolium cations disclosed demonstrate greater or equivalent potency towards cancerous cells as the current clinical standard, cisplatin. These imidazolium cations, however, achieve this efficacy without any of the known toxic side effects caused by heavy metal-based antineoplastic drugs such as cisplatin.
单电荷和多电荷咪唑阳离子(ICs)已被确认为一类具有强效抗肿瘤、抗菌和抗微生物特性的化学物质。所披露的咪唑阳离子对癌细胞表现出比目前临床标准药物顺铂(cisplatin)更强或相当的效力。然而,这些咪唑阳离子在不产生任何重金属类抗肿瘤药物如顺铂所致的已知毒副作用的情况下,实现了这种功效。